4.2 Article

A comparison of antidepressant use in Nova Scotia, Canada and Australia

Journal

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Volume 17, Issue 7, Pages 697-706

Publisher

WILEY
DOI: 10.1002/pds.1541

Keywords

antidepressant; Australia; Canada; utilization; prescribing

Ask authors/readers for more resources

Purpose The prevalence of major depression is reported as approximately 8% in Canada and 7.5% in Australia, the use of antidepressants is therefore common. However, questions remain about whether depression is under-diagnosed and whether patients are appropriately treated with antidepressants once the disorder is recognized. We compared the use of antidepressant medicines, in Nova Scotia, Canada and Australia, in populations receiving public drug subsidy. Methods The Nova Scotia Pharmacare Program and the Pharmaceutical Benefits Scheme in Australia were used to obtain dispensing data for all publicly subsidized antidepressants. Utilization was compared from 2000-2003, using the World Health Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system. Results The use of antidepressants increased in both areas over the study period. However, the use of antidepressants in Nova Scotia increased at a significantly higher rate than Australia. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed class of drugs in both areas, constituting 60% of all antidepressants prescribed. Eight different antidepressants made up 90% of the antidepressant drug use in Australia, with sertraline the most commonly prescribed, Similarly, nine different antidepressants made up 90% of the antidepressant use in Nova Scotia, with paroxetine most commonly prescribed. Conclusions This study found differences in the rate but not class of antidepressant prescribing in Nova Scotia and Australia. Antidepressant use increased in both areas over the time period. This may be due to increased exposure to marketing, promotion, education or different prescribing practices in Nova Scotia compared to Australia. Copyright (c) 2008 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychiatry

Trends of perinatal mental health referrals and psychiatric admissions in Queensland

Macarena A. San Martin Porter, Joemer Maravilla, Steve Kisely, Kim S. Betts, Caroline Salom, Rosa Alati

Summary: The study found that referrals for mental health care during the perinatal period have increased since the implementation of universal screening in Queensland, while admissions for mood disorders in the first 3 months after delivery have decreased.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Review Psychiatry

A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders

Steve Kisely, Mark Connor, Andrew A. Somogyi, Dan Siskind

Summary: Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Article Medicine, General & Internal

Self-reported child maltreatment and cardiometabolic risk in 30-year-old adults

Stephen Kisely, Dan Siskind, James G. Scott, Jake M. Najman

Summary: This study examined the association between childhood maltreatment and obesity and metabolic risk factors. The results showed that emotional abuse and neglect were strongly associated with obesity and several cardiometabolic risk factors.

INTERNAL MEDICINE JOURNAL (2023)

Article Psychiatry

Australian older persons mental health inpatient and ambulatory services in 2015-2020-A descriptive analysis and commentary

Matthew Brazel, Stephen Allison, Tarun Bastiampillai, Stephen Kisely, Samantha M. Loi, Jeffrey C. L. Looi

Summary: The expenditure on older persons mental health services in Australia has not increased at the same rate as other population groups. Mental health of individuals aged over 65 seems to be a neglected policy priority in Australia. The Royal Commission into Aged Care Quality and Safety may lead to changes in services and expenditures.

AUSTRALASIAN PSYCHIATRY (2023)

Article Psychiatry

Commentary on the private practice implications of the Deed of Settlement in the Honeysuckle Health - NIB Australian-Competition-Tribunal-hearing

Jeffrey C. L. Looi, Gary Galambos, William Pring, Stephen Allison, Tarun Bastiampillai, Stephen R. Kisely

Summary: This commentary discusses the implications of the Deed of Settlement in the Honeysuckle Health - nib Australian-Competition-Tribunal Hearing, which has significant implications for a dominant private health insurance buying group and its potential to limit patients' and psychiatrists' clinical autonomy. The Australian Competition and Consumer Commission (ACCC) authorized the formation of a joint buying group in 2021, but a subsequent legal challenge resulted in a settlement that preserves doctor-patient autonomy, transparency of contractual arrangements, and informed consent for the collection of clinical data. However, private health insurers still have options to form new buying groups and collect data on the general public and insured patients.

AUSTRALASIAN PSYCHIATRY (2023)

Article Psychiatry

More smoke and mirrors: Fifteen further reasons to doubt the effectiveness of headspace

Stephen R. Kisely, Tarun Bastiampillai, Stephen Allison, Jeffrey C. L. Looi

Summary: The debate on the effectiveness of headspace and its services has been evaluated independently, and the findings indicate that headspace does not provide therapy for a sufficient duration to result in clinically significant improvement. Most evaluations have used short-term measures or satisfaction surveys without control, and the outcomes using standardized measures have shown disappointing results. The costs are poorly quantified and may be underestimated. Despite this, headspace as a primary care intervention costs twice as much as a mental health consultation by a general practitioner and may not be cost effective, depending on assumptions.

AUSTRALASIAN PSYCHIATRY (2023)

Article Psychiatry

Can improvement in delivery of smoking cessation care be sustained in psychiatry inpatient settings through a system change intervention? An analysis of statewide administrative health data

Sally Plever, Steve Kisely, Billie Bonevski, Irene McCarthy, Brett Emmerson, Emma Ballard, Melissa Anzolin, Dan Siskind, John Allan, Coral Gartner

Summary: This study evaluated the maintenance of improved delivery of smoking cessation assistance in adult acute psychiatry inpatient units three years after the statewide implementation of a system change intervention. The findings indicated that the percentage of discharges with recorded smoking status remained high, surpassing 90% on average.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Editorial Material Psychiatry

The down-scheduling of MDMA and psilocybin(e): Too fast and too soon

Steve Kisely

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Article Psychiatry

Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis

Korinne Northwood, E. Pearson, U. Arnautovska, S. Kisely, M. Pawar, M. Sharma, K. Vitangcol, E. Wagner, N. Warren, Dan Siskind

Summary: Through analyzing the relationship between clozapine blood levels and treatment efficacy, the researchers found that a range of 250-550 ng/mL is recommended, with a particular emphasis on levels above 350 ng/mL yielding the best treatment response. However, the risk and benefits of using blood levels exceeding 550 ng/mL should be weighed.

BRITISH JOURNAL OF PSYCHIATRY (2023)

Article Clinical Neurology

Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)

Matthew K. T. McAdam, Ross J. Baldessarini, Andrea L. Murphy, David M. Gardner

Summary: This study provides dosing equivalencies and recommendations for drugs used to treat psychosis. Survey participants from 24 countries provided consensus on dosing recommendations and equivalency estimates for oral, long-acting injectable, and short-acting injectable formulations. The study found that consensus was highest for long-acting injectable formulations, intermediate for oral agents, and lowest for short-acting injectable formulations.

JOURNAL OF PSYCHOPHARMACOLOGY (2023)

Article Psychiatry

Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)

Dan Siskind, Andrea Baker, Anthony Russell, Nicola Warren, Gail Robinson, Stephen Parker, Sarah Medland, Steve Kisely, Tineka Hager, Urska Arnautovska

Summary: This is a 36-week trial to examine the efficacy of the GLP-1 receptor agonist semaglutide on antipsychotic-induced obesity in individuals with schizophrenia. The study will recruit 80 clozapine-treated patients aged 18-64 and assess the percentage change in body weight as the primary endpoint.

BJPSYCH OPEN (2023)

Article Primary Health Care

New Zealand pharmacists' views regarding the current prescribing courses: questionnaire survey

Mariam Ghabour, Caroline Morris, Kyle Wilby, Alesha Smith

Summary: This study aimed to explore the knowledge and perceptions of New Zealand registered pharmacists on pharmacist prescribing roles, courses, and the barriers and facilitators to course uptake. The findings revealed that most pharmacists believed that pharmacist prescribing would improve healthcare delivery in New Zealand. The main barriers to course uptake included funding, lack of institutional support, inadequate pharmacological/pharmaceutical knowledge, and difficulties in finding medical supervisors.

JOURNAL OF PRIMARY HEALTH CARE (2023)

Article Psychiatry

Can new approaches to synthesising evidence help achieve a consensus in psychotherapy research?

Stephen R. Kisely

Summary: The debate on the interpretation of evidence from randomized control trials (RCTs) on psychodynamic psychotherapy in the College's Clinical Practice Guidelines has brought attention to the differences in opinion. This paper discusses new techniques, such as umbrella reviews, that can help minimize disagreements and foster consensus on treatment guidelines. The latest umbrella review findings suggest that psychodynamic therapy is an evidence-based approach for common mental disorders, among other treatments.

AUSTRALASIAN PSYCHIATRY (2023)

Article Criminology & Penology

Trajectories of Offending and Mental Health Service Use: Similarities and Differences by Gender and Indigenous Status in an Australian Birth Cohort

James M. Ogilvie, Lisa Broidy, Carleen Thompson, Susan Dennison, Troy Allard, Aydan Kuluk, Belinda Crissman, Steve Kisely, Anna Stewart

Summary: This research aims to examine whether there are differences in mental health characteristics and service contacts across patterns of criminal legal system contact and whether these differences are consistent across gender and Indigenous status.

JOURNAL OF DEVELOPMENTAL AND LIFE-COURSE CRIMINOLOGY (2023)

Review Psychology, Clinical

CBTp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis

Aleksandar Todorovic, Sweta Lal, Frances Dark, Veronica De Monte, Steve Kisely, Dan Siskind

Summary: Cognitive behavioural therapy may have small benefits for positive symptoms in clozapine refractory schizophrenia, but does not alter negative symptoms. Given the low risks and limited alternative options, this approach should be considered in this population.

JOURNAL OF MENTAL HEALTH (2023)

No Data Available